ADORE trial enrolls first patient

The pharmaceutical company Ferrer has announced that the first patient has been…

Words Lucie van Leeuwen.Published November 16, 2021
ADORE trial enrolls first patient

The pharmaceutical company Ferrer has announced that the first patient has been enrolled in their ADORE (ALS Deceleration with ORal Edaravone) clinical trial. This Phase III trial will enrol about 300 patients across European countries. It will evaluate how effective and safe FNP122 (an oral formulation of edaravone) is in people living with ALS. TRICALS is pleased to be working together with Ferrer on this trial. The full press release can be found here.

Prof. Leonard H. van den Berg, Chair of TRICALS and Principal Investigator of the study: “The TRICALS consortium is proud to collaborate with Ferrer, since this is an important study, and we look forward to offering further support throughout the course of the trial. We hope oral edaravone will yield a positive outcome and be beneficial for people diagnosed with ALS, as more effective treatments are needed”.

We will post updates on our website once they are available. Would you like to receive news about this trial and other TRICALS activities in your inbox? Click here to subscribe to our newsletter: https://bit.ly/news-letter-TRICALS!


Share

Related news

First participants enrolled in PHOENIX trial
First participants enrolled in PHOENIX trial
Amylyx Pharmaceuticals, Inc. today announced that the first participants have been dosed […]
A road map for digital health care technology in MND
A road map for digital health care technology in MND
The COVID-19 pandemic has had an important impact on the development and […]
The Lalji Family ALS Award
The Lalji Family ALS Award
The Lalji Family ALS Award is a global prize celebrating excellence in […]
More patients eligible for treatment research through innovative study design
More patients eligible for treatment research through innovative study design
Due to a new trial design for treatment research, more ALS patients […]